HIV and hepatitis C co-infection;HIV- und hepatitis-C-koinfektion

Deutsche Medizinische Wochenschrift

Volumn 135, Issue 23, 2010, Pages 1186-1191

  Vogel, M ^a   Boesecke, C ^a   Wasmuth, J C ^a   Rockstroh, J K ^a  

^a UNIVERSITY HOSPITAL BONN   (Germany)

Author keywords

Diagnosis; Hepatitis C; Highly active antiretroviral therapy (HAART); HIV infection; Interferon; Ribavirin

Indexed keywords

ABACAVIR; ABACAVIR PLUS LAMIVUDINE; ABACAVIR PLUS LAMIVUDINE PLUS ZIDOVUDINE; ANTIRETROVIRUS AGENT; ATAZANAVIR; BOCEPREVIR; DARUNAVIR; DIDANOSINE; EFAVIRENZ; EFAVIRENZ PLUS EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; ETRAVIRINE; FOSAMPRENAVIR; INDINAVIR; LOPINAVIR PLUS RITONAVIR; MARAVIROC; NEVIRAPINE; PEGINTERFERON; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RALTEGRAVIR; RIBAVIRIN; RITONAVIR; SAQUINAVIR; STAVUDINE; TELAPREVIR; TENOFOVIR; TIPRANAVIR; ZIDOVUDINE;

ANEMIA; CLINICAL TRIAL; COHORT ANALYSIS; DISEASE COURSE; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; EPIDEMIOLOGICAL DATA; GENOTYPE; HEPATITIS C; HETEROSEXUALITY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INCIDENCE; INFECTION CONTROL; LIPOATROPHY; MIXED INFECTION; PRACTICE GUIDELINE; PREVALENCE; REVIEW; RISK FACTOR; SEROCONVERSION; SEXUAL INTERCOURSE; SURVIVAL RATE; TREATMENT RESPONSE;

AIDS-RELATED OPPORTUNISTIC INFECTIONS; ALGORITHMS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; ANTIVIRAL AGENTS; CROSS-SECTIONAL STUDIES; EVIDENCE-BASED MEDICINE; FOLLOW-UP STUDIES; HEPATITIS C, CHRONIC; HUMANS; INTERFERON ALFA-2A; POLYETHYLENE GLYCOLS; PRACTICE GUIDELINES AS TOPIC; RIBAVIRIN;

EID: 77953152550     PISSN: 00120472     EISSN: 14394413     Source Type: Journal    
DOI: 10.1055/s-0030-1255129     Document Type: Review

References (30)

1. Anonymus: The future of harm reduction programmes in Russia. Lancet 2009 374 1213
2. Bani-Sadr F, Carrat F, Pol S et al. Risk factors for symptomatic mitochondrial toxicity in HIV/hepatitis C virus-coinfected patients during interferon plus ribavirin-based therapy. J Acquir Immune Defic Syndr 2005 40 47-52
3. Bani-Sadr F, Denoeud L et al. Early virologic failure in HIV-coinfected hepatitis C patients treated with the peginterferon-ribavirin combination: does abacavir play a role? J Acquir Immune Defic Syndr 2007 45 123-125
4. Benhamou Y, Bochet M, Di Martino V et al. Liver fibrosis progression in human immunodeficiency virus and hepatitis C virus coinfected patients. The Multivirc Group. Hepatology 1999 30 1054-1058 (Pubitemid 29458296)
5. Berenguer J, Alvarez-Pellicer J, Martin P M. et al. Sustained virological response to interferon plus ribavirin reduces liver-related complications and mortality in patients coinfected with human immunodeficiency virus and hepatitis C virus. Hepatology 2009 50 407-413
6. Cai W, Radun D, Fachgebiet 34 des Robert Koch Instituts. Virushepatitis B, C und D im Jahr 2008. Epidemiologisches Bulletin Nr. 20 vom 18.5.2009.
7. Danta M, Semmo N, Fabris P et al. Impact of HIV on host-virus interactions during early hepatitis C virus infection. J Infect Dis 2008 197 1558-1566
8. Frederick T, Burian P, Terrault N et al. Factors associated with prevalent hepatitis C infection among HIV-infected women with no reported history of injection drug use. AIDS Patient Care STDS 2009 23 915-923
9. Giraudon I, Ruf M, Maguire H et al. Increase in diagnosed newly acquired hepatitis C in HIV-positive men who have sex with men across London and Brighton, 2002-2006. Sex Transm Infect 2008 84 111-115
10. Jones L, Uriel A, Kaplan D et al. Natural History and Treatment Outcome of Acute hepatitis C With and Without HIV Co-infection in a North American Cohort. In, AASLD 2008 Meeting. San Francisco, USA 2008, Abstract 1838
11. Kempf D J., Klein C, Chen H J. et al. Pharmacokinetic enhancement of the hepatitis C virus protease inhibitors VX-950 and SCH 503034 by co-dosing with ritonavir. Antivir Chem Chemother 2007 18 163-167
12. Laufer N, Laguno M, Perez I et al. Abacavir does not influence the rate of virological response in HIV-HCV-coinfected patients treated with pegylated interferon and weight-adjusted ribavirin. Antivir Ther 2008 13 953-957
13. Martin-Carbonero L, Benhamou Y, Puoti M et al. Incidence and predictors of severe liver fibrosis in human immunodeficiency virus-infected patients with chronic hepatitis C. Clin Infect Dis 2004 38 128-133
14. Martin-Carbonero L, Nunez M, Marino A et al. Undetectable hepatitis C virus RNA at week 4 as predictor of sustained virological response in HIV patients with chronic hepatitis C. AIDS 2008 22 15-21
15. Mira J A., Lopez-Cortes L F., Barreiro P et al. Efficacy of pegylated interferon plus ribavirin treatment in HIV/hepatitis C virus co-infected patients receiving abacavir plus lamivudine or tenofovir plus either lamivudine or emtricitabine as nucleoside analogue backbone. J Antimicrob Chemother 2008 62 1365-1373
16. Moreno S, Garcia-Samaniego J, Moreno A et al. Noninvasive diagnosis of liver fibrosis in patients with HIV infection and HCV/HBV co-infection. J Viral Hepat 2009 16 249-258
17. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines on the use of antiretroviral agents in HIV-1 infected adults and adolescents. Department of Health and Human Services: December 1, 2009; 20012161. http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf
18. Pineda J A., Garcia-Garcia J A., Aguilar-Guisado M et al. Clinical progression of hepatitis C virus-related chronic liver disease in human immunodeficiency virus-infected patients undergoing highly active antiretroviral therapy. Hepatology 2007 46 622-630
19. Qurishi N, Kreuzberg C, Luchters G et al. Effect of antiretroviral therapy on liver-related mortality in patients with HIV and hepatitis C virus coinfection. Lancet 2003 362 1708-1713
20. Ramos B, Nunez M, Rendon A et al. Critical role of ribavirin for the achievement of early virological response to HCV therapy in HCV/HIV-coinfected patients. J Viral Hepat 2007 14 387-391
21. Rockstroh J, Benhamou Y, Bhagani S et al. European AIDS Clinical Society (EACS) Guidelines for the clinical management and treatment of chronic hepatitis B and C co-infection in HIV-infected adults 2009. http://www. europeanaidsclinicalsociety.org/guidelines.asp 2009
22. Rockstroh J K., Mocroft A, Soriano V et al. Influence of hepatitis C virus infection on HIV-1 disease progression and response to highly active antiretroviral therapy. J Infect Dis 2005 192 992-1002
23. Schmidt A, Vogel M, Krznaric I et al. The trouble with bleeding: why do HIV-positive gay men get hepatitis C? 12th European AIDS Conference. Cologne, Germany 2009 Abstract BPD1/7
24. Sherman K, Andersen J et al. Sustained long-term antiviral maintenance with pegylated interferon in HCV/HIV-co-infected patients. 15th Conference on Retroviruses and Opportunistic Infections, Boston 2008. Abstract 59
25. Thomson E C., Nastouli E, Main J et al. Delayed anti-HCV antibody response in HIV-positive men acutely infected with HCV. Aids 2009 23 89-93
26. Trevino A, Rivas P, Herrero-Mendoza M et al. Newly Diagnosed HIV-1 Individuals in Spain since year 2000. Non-B subtypes, and hepatitis C and B virus co-infections. 16th Conference on Retroviruses and Opportunistic Infections, Montreal. 2009 Abstract 300
27. Vispo E, Barreiro P, Pineda J A. et al. Low response to pegylated interferon plus ribavirin in HIV-infected patients with chronic hepatitis C treated with abacavir. Antivir Ther 2008 13 429-437 (Pubitemid 352016736)
28. Vogel M, Deterding K, Wiegand J et al. Initial presentation of acute hepatitis C virus (HCV) infection among HIV-negative and HIV-positive individuals-experience from 2 large German networks on the study of acute HCV infection. Clin Infect Dis 2009 49 317-319; author reply 319
29. Vogel M, Page E, Matthews G et al. The use of week 4 HCV-RNA after acute HCV infection (AHC) to predict chronic HCV infection. 17th Conference on Retroviruses and Opportunistic Infections, San Francisco 2010, Abstract 640.
30. Woitas R P., Stoschus B, Terjung B et al. Hepatitis C-associated autoimmunity in patients coinfected with HIV. Liver Int 2005 25 1114-1121